Quanta tirzepatide and what it actually means for UK patients

Why the dose quantity matters less than the prescriber's decision

It is easy to arrive at this topic thinking the main task is choosing a number. In reality, the quantity of tirzepatide you take at any stage is an output of a clinical assessment, not an input you supply. That can feel frustrating when you are used to buying things by selecting a size, but it reflects how the medicine actually works.

Tirzepatide activates two gut-hormone receptors simultaneously (GIP and GLP-1), slowing the rate at which the stomach empties and increasing satiety signals to the brain. This dual action is also why the titration schedule exists: starting at a low quantity gives the body time to adjust before the dose climbs. The tirzepatide overview on our site explains the mechanism in more detail if you want the biology first.

In the SURMOUNT-1 trial, participants who reached the 15 mg dose saw average body-weight reductions of around 20–21% over 72 weeks, as published in the New England Journal of Medicine. That figure is for those who reached the highest quantity, not everyone does, and not everyone needs to. A lower maintenance dose can still produce meaningful results for many people. What matters is reaching the right quantity for your physiology, safely.

What each quantity in the UK range is actually for

The six UK strengths (2.5, 5, 7.5, 10, 12.5 and 15 mg) are not a menu to browse; they are a staircase with clinical logic behind each step. The 2.5 mg pen is a starter quantity whose job is to settle your system, not to drive significant weight loss. Prescribers typically hold patients at each strength for around four weeks before reviewing whether an increase is appropriate.

If you are looking at what the 10 mg strength involves, it sits in the mid-to-upper range of the schedule and is generally reached after several months on treatment. Some people find 10 mg is their maintenance dose; others continue to 12.5 or 15 mg, and you can read about tirzepatide 30 on our site if you want to understand where the dose range may extend beyond the standard UK schedule. The prescriber reviews response, tolerability and any relevant health changes at each stage.

For a broader look at how the licensed dose range breaks down across the UK supply, the tirzepatide dosing guide on our site covers each strength in plain terms. One practical note: because each pen is pre-set at a single strength, there is no way to adjust the quantity mid-pen, another reason dose decisions are made before dispensing, not after.

Cost is part of the picture too. The price of a course of tirzepatide has changed significantly since Eli Lilly revised UK list prices in September 2025, and higher-dose pens cost more than starter pens. Our Mounjaro treatment page gives context on how private pricing is structured, and what a transparent price actually includes.

Deciding whether tirzepatide is the right treatment to explore

If you have reached this page, you are probably weighing up whether tirzepatide is worth pursuing, and perhaps feeling a little uncertain about where to start. That is a reasonable place to be. It is a significant commitment, both medically and financially, and the volume of information online does not always make the decision easier.

The licensed private eligibility is adults with a BMI of 30 or above, or 27 and above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Lower BMI thresholds may apply for certain ethnic backgrounds under UK guidance. BMI alone does not determine approval, a prescriber looks at the full clinical picture, including medications you already take and any relevant medical history.

The comparison question comes up often, too. Tirzepatide and semaglutide (the active ingredient in Wegovy) are both licensed for weight management in the UK, but they work differently. The Mounjaro or tirzepatide page addresses the naming confusion, and our weight-loss treatment overview sets out the broader options if you are not yet sure which medicine makes sense for your situation.

If NHS access is on your mind, it is worth knowing that the NHS rollout of tirzepatide is phased and currently limited to specific BMI and comorbidity thresholds; NICE's appraisal of tirzepatide (TA1026) sets out the eligibility criteria in full. Private treatment through a regulated pharmacy is the alternative for those who do not meet NHS criteria yet, or who would prefer not to wait.

How nume, sorry, how a regulated pharmacy fits into this decision

Let us be direct about what makes a safe, legal route to tirzepatide in the UK. It requires a prescription from a qualified prescriber, dispensed by a pharmacy registered with the GPhC. You can verify any online pharmacy at the GPhC register. A seller offering tirzepatide without a formal clinical assessment is operating outside the law and, in many documented cases, supplying counterfeit products.

At nume, every consultation is read personally by a GPhC-registered Independent Prescriber on the day you submit it. There is no algorithm making decisions. If you are clinically suitable, treatment is dispatched the same day for free next-working-day delivery via DPD, in plain packaging. Our clinical team lead, Mostafa Damghani, oversees the clinical standards that govern every prescription we issue.

Speak to our prescribers through a free consultation if you would like a clinical view on whether tirzepatide is appropriate for you, and, if so, what quantity and schedule makes sense given your circumstances.

Start your free consultation with our prescribers.